NCT02245204CompletedPhase 1
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd1 site in 1 country8 target enrollmentStarted: September 2014Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- Number of adverse events
Study Overview
Brief Summary
The purpose of this study:
Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced malignant tumor subjects;
Detailed Description
- Investigate the tolerance of Chlorogenic acid for injection in human body, determine the Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT) of Chlorogenic acid for injection in the advanced malignant tumor subjects;
- Determine the human pharmacokinetics characteristic of Chlorogenic acid for injection;
- Preliminary observation the effectiveness and effective dose;
- Provide the basis for the dosage regimen of phase II/III.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with pathologic or/and FNAC confirmation of advanced cancer but without effective treatment or with treatment failure;
- •Between 18 and 65 years of age, KPS≥70;
- •According to RECIST 1.1,patients with at least one tumor lesion that can accurately be measured by CT or MRI in at least one dimension with longest diameter to be recorded as >2.0cm by general CT or >1.0cm by spiral CT;
- •Life expectancy of at least three (3) months at the enrollment;
- •Patients who have sufficient baseline organ function and whose laboratory data can meet the following criteria at the enrollment:
- •PLT count≥100×10~9/L,
- •WLB count≥4.0×10~9/L and ≤12×10~9/L,
- •Neutrophil granulocyte count≥2.0×10~9/L,
- •HGB count≥90g/L,
- •Total bilirubin <=1.5 times of ULN,
- •ALT/AST ≤2.5 times of ULN,
- •SCr≤1.5 times of ULN,
- •Normal ECG with LVEF (≥50%) measured by echocardiography;
- •Female patients with negative pregnant test, and male/female patients of reproductive age without pregnancy planning in the next 12 months;
- •Volunteered for the phase 1 trial and sign the informed consent without protest;
Exclusion Criteria
- •Patients who have received large area radiotherapy （>30% marrow capacity）;
- •Patients who suffer from other serious complication, such as uncontrollable infection, myocardial infarction within the past 6 months at the enrollment , uncontrollable hypertension ,thromboembolism and etc.;
- •Symptomatic patients with brain metastases (except for the patients whose brain metastases is controlled to stable status after whole brain radiotherapy);
- •Patients who have received the therapy of chemotherapy within 4 weeks before enrollment;
- •Patients who have used nitrosoureas drug or mitomycin within 6 weeks or tyrosine kinase inhibitor within 2 weeks before enrollment;
- •Patients who have received therapy of major surgery within 6 weeks or biopsy surgery within 2 weeks before enrollment;
- •Patients who or have received radical radiotherapy within 6 weeks or local palliative radiotherapy within 2 weeks before enrollment;
- •Patients who experience grade 2 or more than grade 2 toxicity caused by the past therapies;
- •Patients who have history of drug abuse or alcoholism;
- •Patients who smoke over 5 cigarettes or equivalent tobacco per day;
- •Uncontrollable psychopaths;
- •Pregnant or breast-feeding women, or patients(male and female) who have pregnancy plan;
- •Patients who had received a therapy of another investigational drug within 4 weeks or patients who are still in another clinical trial at the enrollment;
- •Known active hepatitis B/hepatitis C, positive HIV/ syphilis antibody;
- •Patient who need long term treatment of cortical hormone or other immunosuppressive drugs such as visceral organ transplanters;
- •Allergic to the investigational drug;
- •Other patients judged ineligible for enrollment in the study by the investigator (sub-investigator).
Arms & Interventions
Chlorgenic acid, Treatment, powder
Experimental
Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
Intervention: Chlorogenic acid (Drug)
Outcomes
Primary Outcomes
Number of adverse events
Time Frame: Within the first 60 days after the first dose of chlorogenic acid
Secondary Outcomes
- Dose-Limiting Toxicity(Within the first 30 days after the first dose of chlorogenic acid)
- Maximum Tolerated Dose(Within the first 30 days after the first dose of chlorogenic acid)
- Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of chlorogenic acid(Within the first 30 days after the first dose of chlorogenic acid)
- Improvement in cancer-related symptoms and quality of life(Within 1 year after the first dose of chlorogenic acid)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 2
Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM PatientsGBMNCT03758014Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd200
Completed
Phase 1
Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced GlioblastomaGlioblastomaNCT02728349Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd26
Terminated
Phase 1
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory CancerNeoplasmsNCT00547261Sanofi6
Completed
Phase 1
Safety and Pharmacokinetic Profile of CKD-581Multiple MyelomaLymphomaNCT01580371Chong Kun Dang Pharmaceutical39
Unknown
Phase 1
Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma PatientsHigh-grade GliomasNCT03904628Lee's Pharmaceutical Limited15